Also known as: insulin glargine-yfgn
U.S. insulin glargine and biosimilar developments in 2026 included CivicaScript's low-cost launch and California's CalRx rollout. The global insulin biosimilars market reached US$2.5 billion in 2025 and is projected to reach US$6.0 billion by 2033.
Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.
The global biosimilar market is experiencing robust growth, valued at USD 36.79 billion in 2024 and projected to reach USD 282.3 billion by 2035 at a CAGR of 20.35%, driven by patent expirations, cost pressures, and expanding access to biologic therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07076199 |
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes |
RECRUITING | PHASE3 |
| NCT06688123 |
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects |
COMPLETED | PHASE2 |
| NCT06340854 |
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes |
COMPLETED | PHASE3 |
| NCT06269107 |
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) |
COMPLETED | PHASE3 |
| NCT00418522 |
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus |
COMPLETED | PHASE4 |
